Gritstone Oncology (GRTS) Coverage Initiated by Analysts at Raymond James

Share on StockTwits

Raymond James started coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a research note released on Thursday morning, The Fly reports. The firm issued an outperform rating on the stock.

GRTS has been the topic of several other reports. BTIG Research increased their price target on shares of Gritstone Oncology to $31.00 and gave the company a buy rating in a research report on Tuesday, December 11th. HC Wainwright began coverage on shares of Gritstone Oncology in a research report on Thursday, March 7th. They issued a buy rating and a $17.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $22.75.

GRTS stock opened at $10.22 on Thursday. Gritstone Oncology has a 12 month low of $9.66 and a 12 month high of $32.90.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new stake in shares of Gritstone Oncology in the 3rd quarter worth about $142,000. Artal Group S.A. bought a new stake in shares of Gritstone Oncology in the 3rd quarter worth about $2,848,000. Alliancebernstein L.P. acquired a new position in shares of Gritstone Oncology in the 3rd quarter valued at about $285,000. Laurion Capital Management LP acquired a new position in shares of Gritstone Oncology in the 3rd quarter valued at about $1,780,000. Finally, Foresite Capital Management IV LLC acquired a new position in shares of Gritstone Oncology in the 3rd quarter valued at about $2,492,000. 59.28% of the stock is owned by institutional investors.

Gritstone Oncology Company Profile

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

Featured Article: Insider Trading

The Fly

Analyst Recommendations for Gritstone Oncology (NASDAQ:GRTS)

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analyzing MoSys  and Ameri
Analyzing MoSys and Ameri
Zacks: Analysts Expect Lipocine Inc  to Announce -$0.22 EPS
Zacks: Analysts Expect Lipocine Inc to Announce -$0.22 EPS
Baidu  Price Target Lowered to $160.00 at Barclays
Baidu Price Target Lowered to $160.00 at Barclays
EBOS Group  Reaches New 12-Month High at $21.50
EBOS Group Reaches New 12-Month High at $21.50
Altisource Portfolio Solutions  Raised to “Hold” at Zacks Investment Research
Altisource Portfolio Solutions Raised to “Hold” at Zacks Investment Research
Liberum Capital Reaffirms “Hold” Rating for Great Portland Estates
Liberum Capital Reaffirms “Hold” Rating for Great Portland Estates


© 2006-2019 Ticker Report